首页> 外文OA文献 >Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

【2h】

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

机译：依达比星和阿糖胞苷联合吉妥珠单抗奥佐米星（IAGO）用于治疗未经治疗的MDS或高危MDS或AML的患者：EORTC和GIMEMA白血病小组的II期研究（协议06013）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Theo de Witte; Stefan Suciu; Liv Meert; Constantijn Halkes; Dominik Selleslag; Dominique Bron; Sergio Amadori; Roel Willemze; Petra Muus; Frédéric Baron;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) [J] . de Witte Theo, Suciu Stefan, Meert Liv, Annals of hematology . 2015 ,第12期

机译：依达比星和阿糖胞苷联合吉妥珠单抗奥佐米星（IAGO）用于MDS衍生的未经治疗的高危MDS或AML患者：EORTC和GIMEMA白血病组的II期研究（协议06013）
2. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). [J] . R Willemze, S Suciu, P Muus, Annals of hematology . 2014 ,第6期

机译：Clofarabine与预先治疗的中间体和坏风险急性髓性白血病（AML）或高风险骨髓增生综合征（HR-MDS）的患者中的标准缓解诱导方案（胞嘧啶阿拉伯苷和含替代素）组合的患者：持续阶段的阶段 E / II研究EORTC和GIMEMA的白血病组（EORTC Gimema 06061 / AML-14A试验）。
3. Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17) [J] . Sergio Amadou, Stefan Suciu, Roberto Stasi, Journal of Clinical Oncology . 2013 ,第35期

机译：吉姆单抗Ozogamicin和标准化学疗法在新诊断为急性髓性白血病的老年患者中的顺序组合：EORTC和GIMEMA联合会（AML-17）进行的III期随机试验的结果
4. Characterization of Truncation Products of CXCL12 in Patients with MDS or AML Undergoing Phase I/II Trials with ON 01910.Na (rigosertib) [C] . Sool Yeon Cho, Shyamala C Navada, Lewis R. Sliverman, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：在01910.NA（Rigosertib）中，MDS或AML患者中CXCL12截断产物的表征
5. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) [O] . Theo de Witte, Stefan Suciu, Liv Meert, -1

机译：依达比星和阿糖胞苷联合吉妥珠单抗奥佐米星（IAGO）用于治疗未经治疗的MDS或高危MDS或AML的患者：EORTC和GIMEMA白血病小组的II期研究（协议06013）
6. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) [O] . De Witte, Theo, Baron, Frédéric F., Suciu, Stefan, 2015

机译：伊达比星和阿糖胞苷联合吉妥单抗联合奥扎米星（IAGO）用于MDS演变而来的未经治疗的高危MDS或AML患者：EORTC和GIMEMA白血病小组的II期研究（协议06013）

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

著录项

相似文献

相关主题

期刊订阅